PCSK9 and metabolic syndrome: Whereas multiple meta-analyses quantifying the effect size of a treatment and of associated intrinsic and extrinsic factors exist in this field (26, 35, 36), the current research represents, to our knowledge, the first successful attempt to evaluate and specify the relationships between multiple early-phase biomarkers and long-term efficacy outcomes in dyslipidemia treatment under statin or anti-PCSK9 therapies, in the context of 15 individual MACE components, and based on an up-to-date comprehensive analysis of historical data from 54 clinical trials.